FDA
Home Page | CDRH Home Page | Search
| CDRH
A-Z Index | Contact CDRH
|
Guidance for Industry and FDAThe Mammography Quality Standards Act Final Regulations Modifications and Additions to Policy Guidance Help System #8Document issued on October 23, 2003This document modifies and updates guidance appearing
in the Policy Guidance Help System.
|
This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance. |
|
||||||
21 CFR 900.12(e)(8): Use of test results |
||||||
(ii) If the test results fall outside of the action limits, the source of the problem shall be identified and corrective actions shall be taken: | ||||||
(A) |
Before any further examinations are performed or any films are processed using the component of the mammography system that failed any of the tests, described in paragraphs (e)(1), (e)(2), (e)(4)(i), (e)(4)(iii), (e)(5)(vi), (e)(6), or (e)(7) of this section; | |||||
The approved alternative is: |
||||||
21 CFR 900.12(e)(8): Use of test results. |
||||||
(ii) If the test results for the Selenia FFDM System fall outside the action limits, the source of the problem shall be identified and corrective actions shall be taken: | ||||||
(A) |
If any of the following quality control tests that evaluate the performance of the image acquisition components of the Selenia FFDM system produce results that fall outside the action limits as specified by the manufacturer, the source of the problem shall be identified and corrective action shall be taken before any further examinations are performed: | |||||
(1) |
Evaluation of System Resolution | |||||
(2) | Breast Entrance Exposure and Average Glandular Dose | |||||
(3) | Phantom Image Quality Evaluation (Medical Physicist) | |||||
(4) | Phantom Image (Radiologic Technologist) | |||||
(5) | Signal-to-Noise and Contrast-to-Noise Measurements | |||||
(6) | Detector Flat-Field Calibration | |||||
(7) | Compression | |||||
(8) | Post-Move and Pre-Examination Tests for Mobile Selenia FFDM systems | |||||
(B) |
If any of the following quality control tests that evaluate the performance of a diagnostic device used for mammographic image interpretation (i.e. laser printer, physicians review station) produces results that fall outside the action limits as specified by the manufacturer, the source of the problem shall be identified and corrective action shall be taken before that device can be used for mammographic image interpretation. Clinical imaging can be continued and alternative approved diagnostic devices shall be used for mammographic image interpretation: | |||||
(1) |
Phantom Image Quality Evaluation (Medical Physicist) | |||||
(2) | Phantom Image (Radiologic Technologist) | |||||
(3) | Softcopy Workstation QC | |||||
(4) | Laser Printer Quality Control | |||||
(5) | Dark Room Cleanliness | |||||
(6) | Processor Quality Control | |||||
(7) | Viewboxes and Viewing Conditions | |||||
(8) | Darkroom Fog | |||||
(C) |
If any of the following quality control tests that evaluate the performance of components other than the digital image receptor or the diagnostic devices used for mammographic image interpretation produces results that fall outside the action limits as specified by the manufacturer, the source of the problem shall be identified and corrective action shall be taken within thirty days of the test date. Clinical imaging and mammographic image interpretation can be continued during this period: | |||||
(1) |
Mammographic Unit Assembly Evaluation | |||||
(2) | Collimation Assessment | |||||
(3) | Artifact Evaluation | |||||
(4) | kVp Accuracy and Reproducibility | |||||
(5) | Beam Quality Assessment HVL Measurement | |||||
(6) | Radiation Output Rate | |||||
(7) | Viewbox Luminance and Room Illuminance | |||||
(8) | Compression Thickness Indicator | |||||
(9) | Visual Checklist | |||||
(10) | Analysis of Fixer Retention in Film | |||||
(11) | Repeat Analysis | |||||
Amendment to GE SenographeTM 2000D Full Field Digital Mammography (FFDM) system alternative standard originally approved on June 27, 2002. The following amended alternative standard was approved on August 25, 2003 and became effective on the date of approval. The amended standard replaces the specific reference to the GE SenographeTM 2000D FFDM system with a generic reference to an "FDA-approved GE" FFDM system. Like the original standard, it allows a 30 day period for corrective actions following the failure of specified quality control tests by an FDA-approved GE FFDM system. However, it divides into two groups the tests whose failure requires corrective action before the failing component is used again during patient examinations. This division makes it clear that when the test failure is related to the acquisition of images only, the review of already acquired images can continue and when the test failure is related to the image review components only, images can continue to be acquired. Also, in approving the amended alternative standard, FDA stated that if GE introduces new FFDM systems having QC tests other than what is included in the original or amended standard, the subject amended alternative standard would not be applicable to such systems. The original approved alternative standard is 21 CFR 900.12(e)(8)(ii), which states: |
||||||
21 CFR 900.12(e)(8): Use of test results. |
||||||
(ii) If the test results for the SenographeTM 2000D FFDM fall outside of the action limits, the source of the problem shall be identified and corrective actions shall be taken: | ||||||
(A) |
Before any further mammograms are acquired using the SenographeTM 2000D FFDM system that failed any of the following tests: | |||||
(1) |
Monitor cleaning for the Acquisition Work Station (AWS) | |||||
(2) | Flat Field Test | |||||
(3) | CNR Test | |||||
(4) | Phantom Image Quality Test for the AWS | |||||
(5) | MTF Measurement | |||||
(6) | AOP Mode and SNR Check | |||||
(7) | Visual Check List | |||||
(8) | Compression Force Test | |||||
(9) | Average Glandular Dose | |||||
(10) | Post-move, Pre-examination Tests for Mobile SenographeTM 2000D FFDM | |||||
(B) |
Before any further examinations are reviewed or any films are printed or processed using the component of the SenographeTM 2000D FFDM system that failed any of the following tests: | |||||
(1) |
Monitor cleaning for the Review Work Station (RWS) | |||||
(2) | Viewing Conditions for the RWS (Radiologic Technologists test) | |||||
(3) | Viewing Conditions Check and Setting (Medical Physicists test for the RWS) | |||||
(4) | Phantom Image Quality Test for the RWS | |||||
(5) | Phantom Image Quality Test for the Printer | |||||
(6) | Viewbox and Viewing Conditions Test | |||||
(7) | Monitor Calibration Check (Radiologic Technologists test for the RWS) | |||||
(8) | Image QualitySMPTE Pattern (Medical Physicists test for the RWS) | |||||
(9) | Printer QC | |||||
(C) |
Within 30 days of the test date for the following tests: | |||||
(1) |
Repeat Analysis | |||||
(2) | Collimation Assessment | |||||
(3) | Evaluation of Focal Spot Performance | |||||
(4) | Exposure and mAs Reproducibility | |||||
(5) | Artifact Evaluation; Flat Field Uniformity | |||||
(6) | Monitor Calibration (Medical Physicists test for the RWS) | |||||
(7) | Analysis of the RWS Screen Uniformity | |||||
(8) | kVp Accuracy and Reproducibility | |||||
(9) | Beam Quality Assessment (Half-Value Layer Measurement) | |||||
(10) | Radiation Output | |||||
(11) | Mammographic Unit Assembly Evaluation | |||||
The approved amendment to this alternative is stated below: |
||||||
21 CFR 900.12(e)(8): Use of test results. |
||||||
For the image acquisition system | ||||||
(i) If the test results for the image acquisition system of the FDA-approved GE full-field digital mammography (FFDM) equipment fall outside of the action limits, the source of the problem shall be identified and corrective actions shall be taken: | ||||||
(A) |
Before any further mammographic images are acquired using the image acquisition system that failed any of the following tests: | |||||
(1) |
Monitor cleaning for the acquisition work station (AWS) | |||||
(2) | Flat Field Test | |||||
(3) | CNR Test | |||||
(4) | Phantom Image Quality Test for the AWS | |||||
(5) | MTF Measurement | |||||
(6) | AOP Mode and SNR Check | |||||
(7) | Visual Check List | |||||
(8) | Compression Force Test | |||||
(9) | Average Glandular Dose | |||||
(10) | Post-move, Pre-examination Tests for a mobile FDA-approved GE FFDM | |||||
(B) |
Before any further films of mammographic images are printed or processed using the component of the FDA-approved GE FFDM equipment that failed any of the following tests: | |||||
(1) |
Phantom Image Quality Test for the Printer | |||||
(2) | Viewbox and Viewing Conditions Test | |||||
(3) | Printer QC | |||||
(C) |
Within 30 days of the test date for the following tests: | |||||
(1) |
Repeat Analysis | |||||
(2) | Collimation Assessment | |||||
(3) | Evaluation of Focal Spot Performance | |||||
(4) | Exposure and mAs Reproducibility | |||||
(5) | Artifact Evaluation; Flat Field Uniformity | |||||
(6) | kVp Accuracy and Reproducibility | |||||
(7) | Beam Quality Assessment (Half-Value Layer Measurement) | |||||
(8) | Radiation Output | |||||
(9) | Mammographic Unit Assembly Evaluation | |||||
For the image display system |
||||||
(ii) If the test results for the image display system of the FDA-approved GE full-field digital mammography (FFDM) equipment fall outside of the action limits, the source of the problem shall be identified and corrective actions shall be taken: | ||||||
(A) |
Before any further mammographic images are reviewed or any films are printed or processed using the component of the image display system that failed any of the following tests: | |||||
(1) |
Monitor cleaning for the review workstation (RWS) | |||||
(2) | Viewing Conditions for the RWS (Radiologic Technologists test) | |||||
(3) | Viewing Conditions Check and Setting (Medical Physicists test for the RWS) | |||||
(4) | Phantom Image Quality Test for the RWS | |||||
(5) | Phantom Image Quality Test for the Printer | |||||
(6) | Viewbox and Viewing Conditions Test | |||||
(7) | Monitor Calibration Check (Radiologic Technologists test for the RWS) | |||||
(8) | Image QualitySMPTE Pattern (Medical Physicists test for the RWS) | |||||
(9) | Printer QC | |||||
(B) |
Within 30 days of the test date for the following tests: | |||||
(1) |
Monitor Calibration (Medical Physicists test for the RWS) | |||||
(2) | Analysis of the RWS Screen Uniformity. | |||||
No time limit has been placed on the period of approval for this alternative requirement. |
||||||
Modifications in the Assessment Categories Used in Medical Reports |
||||||
Two alternative requirements were approved on August 29, 2003. One of these adds a new assessment category for use in the reports of the mammography examinations and also adds clarifying language to the existing assessment categories. The second adds a reference to the possible need to obtain prior mammograms in order to make a final assessment. The alternatives were approved for an indefinite period. The original standards are 21 CFR 900.12(c)(1)(iv) and (v), which state: |
||||||
21 CFR 900.12(c)(1): Medical records and mammography reports |
||||||
.. | ||||||
(iv) Overall assessment of findings, classified in one of the following categories: | ||||||
(A) | "Negative:" Nothing to comment upon (if the interpreting physician is aware of clinical findings or symptoms, despite the negative assessment, these shall be explained)"; | |||||
(B) | "Benign:" Also a negative assessment; | |||||
(C) | "Probably Benign:" Finding(s) has a high probability of being benign; | |||||
(D) | "Suspicious:" Finding(s) without all the characteristic morphology of breast cancer but indicating a definite probability of being malignant; | |||||
(E) | "Highly suggestive of malignancy:" Finding(s) has a high probability of being malignant: | |||||
(v) In cases where no final assessment category can be assigned due to incomplete work-up, "Incomplete: Need additional imaging evaluation" shall be assigned as an assessment and reasons why no assessment can be made shall be stated by the interpreting physician; and . | ||||||
The approved alternatives are: |
||||||
21 CFR 900.12(c)(1): Medical records and mammography reports |
||||||
.. | ||||||
(iv) Overall assessment of findings, classified in one of the following categories: | ||||||
(A) | "Negative:" Nothing to comment upon (if the interpreting physician is aware of clinical findings or symptoms, despite the negative assessment, these shall be explained)"; | |||||
(B) | "Benign Finding(s):" Also a negative assessment; | |||||
(C) | "Probably Benign Finding:" Initial short-interval follow-up suggested. Finding(s) has a high probability of being benign; | |||||
(D) | "Suspicious Abnormality:" Biopsy should be considered. Finding(s) without all the characteristic morphology of breast cancer but indicating a definite probability of being malignant; | |||||
(E) | "Highly suggestive of malignancy:" Appropriate action should be taken. Finding(s) has a high probability of being malignant: | |||||
(F) | "Known Biopsy Proven Malignancy:" Appropriate action should be taken. | |||||
(v) In cases where no final assessment category can be assigned due to incomplete work-up, "Incomplete: Need additional imaging evaluation and/or prior mammograms for comparison" shall be assigned as an assessment and reasons why no assessment can be made shall be stated by the interpreting physician; and . | ||||||
As was the case with the original standard, only the words in quotation marks are required to be included in the medical report when giving the assessment category or indicating that no final category can be assigned at the present time. The remaining language is intended to provide explanations of the categories in order to promote their consistent use. It is not required to be included in the medical report, although the interpreting physician may do so if he or she wishes. |
||||||
Assessment category for "Post Procedure Mammograms for Marker Placement" |
||||||
This alternative standard was approved on September 17, 2003. This approved assessment category can only be used for a post procedure mammogram to confirm the deployment and position of a breast tissue marker. The lay summary, which must be provided to the patient, must be specific to the procedure. If the facility makes this post procedure examination part of the interventional study instead of a separately charged examination, then it does not fall under MQSA and the approved alternative standard does not apply. The alternative was approved for an indefinite period The original standard is 21 CFR 900.12(c)(1)(iv), which states: |
||||||
21 CFR 900.12(c)(1): Medical records and mammography reports |
||||||
(iv) Overall assessment of findings, classified in one of the following categories: | ||||||
(A) | "Negative:" Nothing to comment upon (if the interpreting physician is aware of clinical findings or symptoms, despite the negative assessment, these shall be explained)"; | |||||
(B) | "Benign:" Also a negative assessment; | |||||
(C) | "Probably Benign:" Finding(s) has a high probability of being benign; | |||||
(D) | "Suspicious:" Finding(s) without all the characteristic morphology of breast cancer but indicating a definite probability of being malignant; | |||||
(E) | "Highly suggestive of malignancy:" Finding(s) has a high probability of being malignant: | |||||
(v) In cases where no final assessment category can be assigned due to incomplete work-up, "Incomplete: Need additional imaging evaluation" shall be assigned as an assessment and reasons why no assessment can be made shall be stated by the interpreting physician; and... | ||||||
The granted alternative is: |
||||||
21 CFR 900.12(c)(1): Medical records and mammography reports |
||||||
(iv) Overall assessment of findings, classified in one of the following categories: | ||||||
(A) | "Negative:" Nothing to comment upon (if the interpreting physician is aware of clinical findings or symptoms, despite the negative assessment, these shall be explained)"; | |||||
(B) | "Benign:" Also a negative assessment; | |||||
(C) | "Probably Benign:" Finding(s) has a high probability of being benign; | |||||
(D) | "Suspicious:" Finding(s) without all the characteristic morphology of breast cancer but indicating a definite probability of being malignant; | |||||
(E) | "Highly suggestive of malignancy:" Finding(s) has a high probability of being malignant: | |||||
(F) | "Post Procedure Mammograms for Marker Placement" | |||||
(v) In cases where no final assessment category can be assigned due to incomplete work-up, "Incomplete: Need additional imaging evaluation" shall be assigned as an assessment and reasons why no assessment can be made shall be stated by the interpreting physician; and...^- |
Updated October 30, 2003
CDRH Home Page | CDRH A-Z Index | Contact CDRH | Accessibility | Disclaimer
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | HHS Home Page
Center for Devices and Radiological Health / CDRH